REG - Seed Innovations Ltd - Commencement of Share Buy-Back Programme

Seed InnovationsAnnouncement

29/09/2023 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230929:nRSc2343Oa&default-theme=true

RNS Number : 2343O  Seed Innovations Limited  29 September 2023

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) No. 596/2014, as it forms part of UK Domestic
Law by virtue of the European Union (Withdrawal) Act 2018. Upon the
publication of this announcement, this inside information is now considered to
be in the public domain.

29 September 2023

SEED Innovations Limited

("SEED" or the "Company")

Commencement of Share Buy-Back Programme

SEED Innovations Ltd, the AIM-quoted company investment company providing
shareholders with exposure to early-stage health, wellness and medical
cannabis companies to which, in normal circumstances, they have limited access
to, is pleased to announce, further to the announcement of 19 September 2023,
the commencement of a share repurchase programme of Ordinary Shares for up to
a maximum of 21,500,000 shares and £850,000 (the "Programme").

Any purchase of Ordinary Shares made in relation to this announcement will be
carried out on the open market during the period commencing on 2 October 2023
and ending not later than 29 February 2024. The Programme will be funded from
the Company's existing cash resources.

Share purchases will take place in open market transactions and may be made
from time to time depending on market conditions, share price, trading volume
and other factors.  The Company has appointed Shard Capital Partners LLP to
manage the Programme and make market purchases of Ordinary Shares on its
behalf, independently of the Company.

The shares purchased by the Company will be held in treasury pending
cancellation or re-issue.

The Programme will be conducted within the safe harbour parameters of the
Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation
2016/1052/EU (each as incorporated into UK domestic law by the European Union
(Withdrawal) Act 2018, including where relevant pursuant to the Market Abuse
(Amendment) (EU Exit) Regulations 2019). Details of all purchases made
pursuant to the Programme will be announced via RNS and published on the
Company's website as required by the Market Abuse Regulations.

Further information on the Programme is set out in the Company's announcement
dated 19 September 2023.

 

-Ends-

For further information on the Company please visit:  www.seedinnovations.co
(http://www.seedinnovations.com/) or contact:

 Ed McDermott       SEED Innovations Ltd         E: info@seedinnovations.co

 Lance de Jersey
 James Biddle       Beaumont Cornish Limited,    T: (0)20 7628 3396

 Roland Cornish     Nomad
 Isabella Pierre    Shard Capital Partners LLP   T: (0)20 7186 9927

 Damon Heath        Broker
 Catherine Leftley  St Brides Partners Ltd,      E: seed@stbridespartners.co.uk

 Ana Ribeiro        Financial PR

 Isabelle Morris

Notes

Seed Innovations Ltd

SEED Innovations is an AIM quoted investment company focused primarily on
disruptive high growth life sciences and technology businesses particularly
within the medical cannabis arena. The Company's strategy is to identify
early-stage opportunities that have an upcoming investment catalyst and grow
its portfolio in terms of value whilst limiting the number of investee
companies to a level where relevant time can be devoted to each.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSLLMATMTBTBRJ